XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 12,556 $ 7,935
Short-term investments 12,069 10,734
Prepaid clinical trial expenses 396 748
Other prepaid expenses and current assets 197 248
Total current assets 25,218 19,665
Property and equipment, net 118 119
Other assets 11 10
Total assets 25,347 19,794
Current liabilities:    
Accounts payable 2,016 1,998
Accrued clinical trial costs 1,230 820
Accrued expenses 1,213 866
Total current liabilities 4,459 3,684
Promissory note 8,600 0
Warrant liability 1,400 1,700
Total liabilities 14,459 5,384
Commitments and contingencies (Note 8)
Stockholders' equity    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 0 0
Common stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 13,971,990 and 13,481,917, issued and outstanding at March 31, 2025 and December 31, 2024, respectively 4 4
Additional paid-in capital 175,691 174,166
Accumulated deficit (164,806) (159,764)
Accumulated other comprehensive (loss) income (1) 4
Total stockholders' equity 10,888 14,410
Total liabilities and stockholders' equity $ 25,347 $ 19,794